The cemetery is located in the south-west of Pottenbrunn, on plot "Steinfeld" (15°41´05"/48°13´55"). Discovered in 1930, it had already yielded objects dating to the early La Tène period. In 1981, road construction revealed further finds which initiated rescue excavations by the Bundesdenkmalamt (State Office for Protection of Historical Monuments) under the guidance of J.-W. Neugebauer (Ramsl 2002a(Ramsl , 13) in 1981(Ramsl and 1982. A total of 42 graves with 45 burials (single and double inhumations, and cremations) have been documented. Some burials were severely disturbed (by ancient activities such as grave robbing and/or contemporary construction work), and some were set within fenced enclosures ("Grabgärten"). Three (of 22) samples of charcoal and bone fragments taken by Peter Stadler (Department of Prehistory, Natural History Museum Vienna) in the course of the FWFproject "Absolute Chronology for Early Civilisations in Austria and Central Europe" returned AMS dates of 410-200 cal BCE (grave 520), 550-200 cal BCE (grave 565) and 380-350 cal BCE (grave 1005) (Ramsl 2002b, 359). The cremation burials were not included in the initial osteological analysis, but 31 inhumed individuals were studied (Gerold 2002). Petrous bones from three of these were successfully analyzed for aDNA. Sample I11699 (female) derived from an individual (inv. no. 26.238) aged c. 20 years in grave 89 which, despite disturbance in antiquity, was accompanied by fibulae and ceramic vessels. Sample I11701 (male) derived from an individual (inv. no. 26.249) aged c. 18 years in grave 570, which also included shears, fibulae, and ceramic vessels. Evidence for bone porosity in the mandible and maxilla suggest possible Vitamin C deficiency, while enamel hypoplasia points to malnutrition or illness during childhood. Sample I11708 (female) derived from an individual (inv.no. 26.250) aged c. 25-35 years in grave 574/2, who was richly adorned with fibulae, bronze, iron and silver-rings, an amber ring, a bracelet, a glass bead, and a worked bone artefact.
A short period of oxygenated machine perfusion (MP) after static cold storage (SCS) may reduce biliary injury in donation after cardiac death (DCD) donor livers. However, the ideal perfusion temperature for protection of the bile ducts is unknown. In this study, the optimal perfusion temperature for protection of the bile ducts was assessed. DCD rat livers were preserved by SCS for 6 hours. Thereafter, 1 hour of oxygenated MP was performed using either hypothermic machine perfusion, subnormothermic machine perfusion, or with controlled oxygenated rewarming (COR) conditions. Subsequently, graft and bile duct viability were assessed during 2 hours of normothermic ex situ reperfusion. In the MP study groups, lower levels of transaminases, lactate dehydrogenase (LDH), and thiobarbituric acid reactive substances were measured compared to SCS. In parallel, mitochondrial oxygen consumption and adenosine triphosphate (ATP) production were significantly higher in the MP groups. Biomarkers of biliary function, including bile production, biliary bicarbonate concentration, and pH, were significantly higher in the MP groups, whereas biomarkers of biliary epithelial injury (biliary gamma-glutamyltransferase [GGT] and LDH), were significantly lower in MP preserved livers. Histological analysis revealed less injury of large bile duct epithelium in the MP groups compared to SCS. In conclusion, compared to SCS, end-ischemic oxygenated MP of DCD livers provides better preservation of biliary epithelial function and morphology, independent of the temperature at which MP is performed. End-ischemic oxygenated MP could reduce biliary injury after DCD liver transplantation. Liver Transpl 21:1300-1311, 2015. V C 2015 AASLD.Received March 17, 2015; accepted June 8, 2015.Ischemic cholangiopathy, also known as nonanastomotic biliary strictures (NAS), is one of the most prevalent and troublesome complications after liver transplantation. During NAS formation, in particular, the large (extrahepatic) bile ducts become fibrotic and/or necrotic. Patients with NAS may suffer from recurrent jaundice and episodes of cholangitis, and retransplantation may be the only curative treatment. 1 The combination of ischemia and ischemia/ reperfusion (I/R) injury has been shown to be a major Additional supporting information may be found in the online version of this article.
Current guidelines for air travel state that patients with chronic respiratory diseases are required to use oxygen if their in-flight arterial oxygen tensions (Pa,O 2 ) drop below 6.6 kPa. This recommendation may not be strictly applicable to cystic fibrosis patients, who may tolerate lower Pa,O 2 for several hours without clinical symptoms.Lung function, symptoms, blood gas levels and signs of pulmonary hypertension were studied in 36 cystic fibrosis patients at altitudes of 530 m and, after 7 h, 2,650 m. A hypoxia inhalation test (inspiratory oxygen fraction 0.15) was performed at low altitude in order to predict high-altitude hypoxaemia.Median Pa,O 2 dropped from 9.8 kPa at low altitude to 7.0 kPa at high altitude. Mild exercise at a workload of 30 W further decreased Pa,O 2 . Two-thirds of all patients exhibited Pa,O 2 of ,6.6 kPa during exercise and, except for one patient, were asymptomatic. Patients were significantly less obstructed at an altitude of 2,650 m. Low forced expiratory volume in one second at baseline was associated with a low Pa,O 2 at altitude.It is concluded that cystic fibrosis patients with baseline arterial oxygen tensions of .8.0 kPa safely tolerate an altitude of 2,650 m for several hours under resting conditions. The risk assessment of low in-flight oxygenation should encompass the whole clinical situation of cystic fibrosis patients, with special attention being paid to the presence of severe airway obstruction.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.